We hypothesized the change of these parameters after DPP4-inhibitor treatment could be a potential prognostic biomarker for the CRC patients, hence compared these parameters before and after DPP4-inhibitor treatment in these CRC patients with good (n = 8) or poor overall survival (n = 2). This evidence concerns the gene DPP4 and colorectal carcinoma.